Clinical trials

The purpose of this study is to generate clinical evidence on valve safety and performance in subjects treated by redo TAVR.

We are doing this study because we want to find out if this approach is better or worse than the 
usual approach for your liver cancer. The usual approach is defined as care most people get for 
liver cancer.

We are doing this study because we want to find out if this combination is better or worse than the 
usual approach for advanced pancreatic cancer without KRAS mutations. The usual approach, 
which is chemotherapy alone, is defined as the care most people get for advanced or metastatic 
pancreatic cancer.

To evaluate the safety and effectiveness of Magenta Elevate™ compared with Impella® in subjects undergoing non-emergent, MCS-supported HR-PCI. The Primary Outcome Measure will be assessed by comparing the incidence of a composite of major safety adverse events and effectiveness parameters through 30 days.

The purpose of this study is to investigate cemiplimab with or without fianlimab with the hypothesis that the combination will have additive or synergistic effects that may provide clinical benefit in participants with head and neck cancers.

Demonstrate that early implantation of a PA hemodynamic monitor is effective to reduce heart failure hospitalizations, and all-cause mortality, with improved health related quality of life following CS.

CA2400030 is a randomized Phase 2/3 study of BMS-986504 in combination with nab-p/gem versus placebo in combination with nab-p/gem, in participants with untreated metastatic PDAC with homozygous MTAP deletion.  

Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatment with 24 weeks of vincristine and dactinomycin (VA) and examines the use of centralized molecular risk stratification in the treatment of rhabdomyosarcoma. Another aim of the study it to find out how well patients with low risk rhabdomyosarcoma (LR-RMS) respond to standard chemotherapy when patients with VLR-RMS and patients who have rhabdomyosarcoma with DNA mutations get separate treatment. Finally, this study examines the effect of therapy intensification in patients who have RMS cancer with DNA mutations to see if their outcomes can be improved.

This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following platinum-based chemotherapy and anti-PD-1/anti-PD-L1 therapy.

This study aims to see if Puxi-Sam allows participants to live longer without their endometrial cancer getting worse, or simply live longer, compared to participants receiving standard of care chemotherapy. This study is also looking to see how the treatment and the endometrial cancer affect participants' quality of life.

The primary objective of this multicohort phase 1b/2 study is to determine the RP2D of ASP546C (XNW27011) monotherapy based on the totality of efficacy, safety and PK data collected at 2 different dose levels. The secondary objectives include evaluation of the efficacy, safety, PK and immunogenicity of ASP546C monotherapy. Safety and tolerability will be assessed via AEs, SAEs, ECOG performance status, vital signs and other laboratory results.